Evogene (NASDAQ:EVGN) Director Acquires $294,400.00 in Stock

Evogene Ltd. (NASDAQ:EVGN) Director Leon Recanati purchased 460,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was acquired at an average price of $0.64 per share, for a total transaction of $294,400.00. Following the acquisition, the director directly owned 1,343,886 shares of the company’s stock, valued at $860,087.04. This trade represents a 52.04% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Evogene Stock Down 12.6%

Evogene stock opened at $0.61 on Thursday. Evogene Ltd. has a 52-week low of $0.37 and a 52-week high of $1.50. The firm has a fifty day moving average of $0.53 and a 200-day moving average of $0.73. The firm has a market capitalization of $5.33 million, a P/E ratio of -0.44 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last posted its earnings results on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.33). Evogene had a negative net margin of 638.12% and a negative return on equity of 158.82%. The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.35 million.

Hedge Funds Weigh In On Evogene

A number of institutional investors have recently added to or reduced their stakes in EVGN. Citadel Advisors LLC grew its stake in shares of Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 36,206 shares in the last quarter. Jane Street Group LLC boosted its holdings in Evogene by 58.0% in the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Evogene in the fourth quarter valued at about $25,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a report on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.